Beranda › Kanker Paru Non-Sel Kecil › Ohio › Akron
Uji klinis Kanker Paru Non-Sel Kecil di Akron, OH
22 studi untuk Kanker Paru Non-Sel Kecil mencari peserta di lokasi sekitar Akron (dalam radius sekitar 30 mil). Buka studi untuk melihat kriteria peserta dan cara menghubungi tim studi.
Teks studi resmi (Bahasa Inggris)
Merekrut peserta untuk studi di sini? Tampilkan di bagian atas halaman ini — $99 selama 30 hari →
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
Menerima pesertaFase 3
- Cleveland Clinic Akron General, Akron
- Aultman Health Foundation, Canton · 21 mi jauhnya
Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial
Menerima pesertaFase 3
- Aultman Health Foundation, Canton · 21 mi jauhnya
A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)
Menerima pesertaFase 3
- Akron General Medical Center, Akron
Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Menerima pesertaFase 3
- Aultman North, North Canton · 15 mi jauhnya
- Aultman Massillon, Massillon · 20 mi jauhnya
- Aultman Orrville Hospital, Orrville · 21 mi jauhnya
- dan 2 lainnya
A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung Cancer
Menerima pesertaFase 3
- Research Site, Canton · 21 mi jauhnya
Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
Menerima pesertaFase 3
- Aultman Hospital, Canton · 21 mi jauhnya
Pan-tumor MRD Study
Menerima pesertaStudi observasional
- Gabrail Cancer Center, Canton · 21 mi jauhnya
Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer
Menerima pesertaFase 2/3
- Gabrail Cancer Center Research, Canton · 21 mi jauhnya
A Study of Navlimetostat (BMS-986504) Alone or in Combination With Izalontamab Brengitecan in Participants With Pre-treated Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) With Homozygous MTAP Deletion or MTAP Loss (MountainTAP-9)
Menerima pesertaFase 2
- Gabrail Cancer Center, Canton · 21 mi jauhnya
Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
Menerima pesertaFase 2/3
- Tricounty Hematology and Oncology - Massillon, Massillon · 20 mi jauhnya
Quaratusugene Ozeplasmid (Reqorsa) and Osimertinib in Patients With Advanced Lung Cancer Who Progressed on Osimertinib
Menerima pesertaFase 1/2
- Gabrail Cancer Center Research, Canton · 21 mi jauhnya
Study of Trastuzumab Deruxtecan, Pembrolizumab, and Platinum-based Chemotherapy in First-line HER2 Overexpressing Non-small Cell Lung Cancer
Menerima pesertaFase 3
- Gabrail Cancer Center, Canton · 21 mi jauhnya
Efficacy & Safety of Olvimulogene Nanivacirepvec & Platinum-doublet + Physician's Choice of Immune Checkpoint Inhibitor Compared to Docetaxel in NSCL Cancer
Menerima pesertaFase 2
- Gabrail Cancer and Research Center, Canton · 21 mi jauhnya
Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)
Menerima pesertaFase 2
- Cleveland Clinic Mercy Hospital, Canton · 21 mi jauhnya
- Aultman Health Foundation, Canton · 21 mi jauhnya
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial)
Menerima pesertaFase 2
- Aultman Health Foundation, Canton · 21 mi jauhnya
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)
Menerima pesertaFase 2
- Aultman Health Foundation, Canton · 21 mi jauhnya
Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)
Menerima pesertaFase 2/3
- Aultman Health Foundation, Canton · 21 mi jauhnya
GEMINI-NSCLC: NSCLC Biomarker Study
Menerima pesertaStudi observasional
- Aultman Hospital, Canton · 21 mi jauhnya
Phase 1 Study Evaluating the Safety and PK of ADU-1805 in Advanced Solid Tumors
Menerima pesertaFase 1
- Gabrail Cancer & Research Center, Canton · 21 mi jauhnya
A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors
Menerima pesertaFase 1/2
- Research Site 138, Canton · 21 mi jauhnya
A Study Assessing KB707 for the Treatment of Advanced Solid Tumor Malignancies Affecting the Lungs
Menerima pesertaFase 1/2
- Gabrail Cancer Center Research, Canton · 21 mi jauhnya
FIH Trial of VERT-002 in Patients With Locally Advanced or Metastatic Solid Tumors With MET Alterations
Menerima pesertaFase 1/2
- Gabrail Cancer Research Center, Canton · 21 mi jauhnya
Uji klinis Kanker Paru Non-Sel Kecil di kota lain
- Houston, TX145 studi
- New York City, NY120 studi
- Arlington, VA104 studi
- Nashville, TN97 studi
- Boston, MA90 studi
- Los Angeles, CA87 studi
- St. Louis, MO73 studi
- Chicago, IL61 studi
- Baltimore, MD60 studi
- San Antonio, TX59 studi
- Columbus, OH56 studi
- Washington, DC55 studi
Studi lain di Akron
- Kanker Paru16 studi
- Kanker (semua jenis)13 studi
- Kanker Payudara13 studi
- Kanker Prostat9 studi
- Leukemia Mieloid Akut8 studi
- Melanoma8 studi
- Kanker Paru Sel Kecil8 studi
- Kanker Metastatik8 studi
- Kanker Kolorektal8 studi
- Penyakit Hati Steatotik7 studi
- Kanker Endometrium6 studi
- Kanker Ovarium6 studi
Dari ClinicalTrials.gov, data diambil 5 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.